Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H9N3O2 |
Molecular Weight | 155.1546 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CNC=N1)C(O)=O
InChI
InChIKey=HNDVDQJCIGZPNO-YFKPBYRVSA-N
InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1
Molecular Formula | C6H9N3O2 |
Molecular Weight | 155.1546 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1123426Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15612036 | http://www.sciencedirect.com/science/article/pii/S0010854504002371 | https://www.drugs.com/drp/custodiol-htk-solution.html | http://www.pharmanovia.com/fileadmin/user_upload/Pdf_filer/Custodiol_Package_Insert_09-04-03.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1123426
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15612036 | http://www.sciencedirect.com/science/article/pii/S0010854504002371 | https://www.drugs.com/drp/custodiol-htk-solution.html | http://www.pharmanovia.com/fileadmin/user_upload/Pdf_filer/Custodiol_Package_Insert_09-04-03.pdf
Histidine is an essential amino acid. L-histidine is converted to histamine by histidine decarboxylase, a pyridoxal 5'-phosphate-dependent enzyme. The copper(II)–l-histidine (1:2 complex at physiological pH) has been widely used in the treatment of Menkes disease (a genetic neurodegenerative disorder that leads to early death in the children due to impaired copper metabolism) and more recent use has been reported in the treatment of infantile hypertrophic cardioencephalomyopathy (a condition caused by mutations in SCO2, a cytochrome c oxidase assembly gene). CUSTODIOL HTK (Histidine-tryptophan-ketoglutarate) Solution is indicated for perfusion and flushing of donor kidneys, liver, and heart prior to removal from the donor or immediately after removal from the donor.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P19113 Gene ID: 3067.0 Gene Symbol: HDC Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FreAmine III Approved Use3% FreAmine® III (Amino Acid Injection) with Electrolytes is designed for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition. In medical or routine postsurgical patients where enteral nutrition is not desirable or cannot be tolerated, protein sparing can be achieved by the peripheral infusion of amino acid solutions with or without nonprotein calories. Launch Date1971 |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15809910 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Use of molecular beacons to verify that the serine hydroxymethyltransferase pseudogene SHMT-ps1 is unique to the order Primates. | 2001 |
|
Protein histidine kinase. | 2001 |
|
Disruption of an active site hydrogen bond converts human heme oxygenase-1 into a peroxidase. | 2001 Apr 6 |
|
Pumping capacity of bacterial reaction centers and backpressure regulation of energy transduction. | 2001 Feb |
|
Genetic and transcriptional analysis of absA, an antibiotic gene cluster-linked two-component system that regulates multiple antibiotics in Streptomyces coelicolor. | 2001 Feb |
|
The folate cycle and disease in humans. | 2001 Feb |
|
Active site characterization of the single endo-polygalacturonase produced by Fusarium moniliforme NCIM 1276. | 2001 Feb |
|
Three-dimensional structure of the histidine-containing phosphocarrier protein (HPr) from Enterococcus faecalis in solution. | 2001 Feb |
|
The ptsH gene from Bacillus thuringiensis israelensis. Characterization of a new phosphorylation site on the protein HPr. | 2001 Feb |
|
Refolding and purification of Bothropstoxin-I, a Lys49-phospholipase A2 homologue, expressed as inclusion bodies in Escherichia coli. | 2001 Feb |
|
Molecular specificities of antibodies against ovine and murine recombinant prion proteins. | 2001 Feb 16 |
|
Angiotensin I-converting enzyme transition state stabilization by HIS1089: evidence for a catalytic mechanism distinct from other gluzincin metalloproteinases. | 2001 Feb 16 |
|
High resolution structure of the phosphohistidine-activated form of Escherichia coli cofactor-dependent phosphoglycerate mutase. | 2001 Feb 2 |
|
Involvement of acetyl phosphate in the in vivo activation of the response regulator ComA in Bacillus subtilis. | 2001 Feb 20 |
|
Kinetic and mechanistic properties of biotin sulfoxide reductase. | 2001 Feb 6 |
|
Replacement of the axial histidine ligand with imidazole in cytochrome c peroxidase. 2. Effects on heme coordination and function. | 2001 Feb 6 |
|
Replacement of the axial histidine ligand with imidazole in cytochrome c peroxidase. 1. Effects on structure. | 2001 Feb 6 |
|
Crystal structure of auracyanin, a "blue" copper protein from the green thermophilic photosynthetic bacterium Chloroflexus aurantiacus. | 2001 Feb 9 |
|
The pagetoid variant of urothelial carcinoma in situ of urinary bladder in a cow. | 2001 Jan |
|
An amicyanin C-terminal loop mutant where the active-site histidine donor cannot be protonated. | 2001 Jan |
|
Rapid deposition of wheat cell wall structural proteins in response to Fusarium-derived elicitors. | 2001 Jan |
|
The effect of amino acid-modifying reagents on chloroplast protein import and the formation of early import intermediates. | 2001 Jan |
|
Synergistic antidiabetic activities of zinc, cyclo (his-pro), and arachidonic acid. | 2001 Jan |
|
Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). | 2001 Jan |
|
Proximal cysteine residue is essential for the enzymatic activities of cytochrome P450cam. | 2001 Jan |
|
Polyphyletic evolution of type II restriction enzymes revisited: two independent sources of second-hand folds revealed. | 2001 Jan |
|
Two types of putative nuclear factors that physically interact with histidine-containing phosphotransfer (Hpt) domains, signaling mediators in His-to-Asp phosphorelay, in Arabidopsis thaliana. | 2001 Jan |
|
In vitro catabolism of histidine by mixed rumen bacteria and protozoa. | 2001 Jan |
|
Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH. | 2001 Jan 12 |
|
Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis. | 2001 Jan 12 |
|
Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates. | 2001 Jan 12 |
|
Structures of prolyl oligopeptidase substrate/inhibitor complexes. Use of inhibitor binding for titration of the catalytic histidine residue. | 2001 Jan 12 |
|
The coenzyme b12 analog 5'-deoxyadenosylcobinamide-gdp supports catalysis by methylmalonyl-coa mutase in the absence of trans-ligand coordination. | 2001 Jan 12 |
|
Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site. | 2001 Jan 16 |
|
Effect of metal binding on electrogenic proton transfer associated with reduction of the secondary electron acceptor (QB) in Rhodobacter sphaeroides chromatophores. | 2001 Jan 16 |
|
Expression and purification of polyhistidine-tagged firefly luciferase in insect cells--a potential alternative for process scale-up. | 2001 Jan 23 |
|
Genotoxic effects of methyl isothiocyanate. | 2001 Jan 25 |
|
Direct evidence for the protonation of aspartate-75, proposed to be at a quinol binding site, upon reduction of cytochrome bo3 from Escherichia coli. | 2001 Jan 30 |
|
Molecular engineering of myoglobin: the improvement of oxidation activity by replacing Phe-43 with tryptophan. | 2001 Jan 30 |
|
Protein control of the redox potential of the primary quinone acceptor in reactioncCenters from Rhodobacter sphaeroides. | 2001 Jan 30 |
|
Single-molecule measurements calibrate green fluorescent protein surface densities on transparent beads for use with 'knock-in' animals and other expression systems. | 2001 Jan 30 |
|
Histidylated polylysine as DNA vector: elevation of the imidazole protonation and reduced cellular uptake without change in the polyfection efficiency of serum stabilized negative polyplexes. | 2001 Jan-Feb |
|
Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma. | 2001 Mar |
|
Incomplete dialysis of protein samples containing 3-[(3-chlolamidopropyl)dimethylammonio]-1-propanesulfonate may lead to erroneous estimation of histidine content on amino acid analysis. | 2001 Mar 1 |
|
Spectral and metal-binding properties of three single-point tryptophan mutants of the human transferrin N-lobe. | 2001 Mar 1 |
|
Quaternary structure of rice nonsymbiotic hemoglobin. | 2001 Mar 2 |
|
Role of two histidines in the (6-4) photolyase reaction. | 2001 Mar 30 |
|
Identification of the collagen-binding site of the von Willebrand factor A3-domain. | 2001 Mar 30 |
|
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa. | 2001 Mar 9 |
|
Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. | 2001 Mar-Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/342692
Rheumatoid arthritis patients were treated with L-histidine 4.5 g daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16107255
Histidine significantly inhibited both hydrogen peroxide- and TNF-alpha-induced IL-8 secretion and mRNA expression in Caco-2 cells and HT-29 cells. These inhibitions were dose dependent and the inhibition rate of hydrogen peroxide-induced IL-8 secretion reached more than 50% at a concentration of 25 mM, with over 95% inhibition at a concentration of 50 mM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:54 GMT 2023
by
admin
on
Fri Dec 15 15:00:54 GMT 2023
|
Record UNII |
4QD397987E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
27972-9
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
15133-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47649-9
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
15139-9
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
20645-8
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47647-3
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
58930-9
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2420-8
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
25440-9
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
21056-7
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
26808-6
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
27111-4
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
13757-0
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2418-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47648-1
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47643-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47646-5
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
44372-1
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2424-0
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
32246-1
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2423-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
22703-3
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
56683-6
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
9453-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
32247-9
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47644-0
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
JECFA EVALUATION |
L-HISTIDINE
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2422-4
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
30047-5
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2421-6
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
25926-7
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
58927-5
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
2419-0
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
55874-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
25927-5
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
DSLD |
1766 (Number of products:719)
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
58921-8
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
13398-3
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
27904-2
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
DSLD |
176 (Number of products:100)
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
21057-5
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
47645-7
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
||
|
LOINC |
22717-3
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
29979
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
m6028
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
D006639
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
4QD397987E
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
137773
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
57595
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
200-745-3
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
1421
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
5340
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
1810
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
DB00117
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL17962
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
4QD397987E
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
15971
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
1377
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
SUB20034
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
71-00-1
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
27570
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
DTXSID9023126
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
SUB08045MIG
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
100000092646
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
1308505
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
HISTIDINE
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
6163
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
6274
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY | |||
|
C29597
Created by
admin on Fri Dec 15 15:00:54 GMT 2023 , Edited by admin on Fri Dec 15 15:00:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |